SUPPLEMENTAL MATERIAL

Figure 1: One-way sensitivity analysis for dabigatran etexilate versus any control treatment (Fixed-effect model)

A. Myocardial infarction

Risk of myocardial infarction : Dabigatran (any dose) vs any comparators

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	1,457	1,002	2,118	1,968	0,049
PETRO	1,333	1,080	1,647	2,671	0,008
RE-COVER	1,328	1,073	1,642	2,612	0,009
RE-MEDY	1,279	1,032	1,584	2,249	0,025
RE-NOVATE	1,388	1,117	1,724	2,960	0,003
RE-MODEL	1,340	1,081	1,661	2,672	0,008
RE-NOVATE II	1,339	1,084	1,654	2,705	0,007
RE-MOBILIZE	1,360	1,093	1,693	2,758	0,006
RE-DEEM	1,311	1,054	1,631	2,435	0,015
RE-SONATE	1,339	1,084	1,654	2,706	0,007
RE-ALIGN	1,324	1,071	1,636	2,599	0,009
RE-COVER II	1,327	1,073	1,642	2,610	0,009
	1,336	1,082	1,650	2,696	0,007



Sensitivity analysis

B. Other cardiovascular events

Risk of others cardiovascular diseases: Dabigatran (any dose) vs any comparators

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	0,949	0,568	1,586	-0,199	0,842
RE-COVER	0,934	0,827	1,055	-1,103	0,270
RE-DEEM	0,935	0,826	1,059	-1,051	0,293
RE-MEDY	0,932	0,825	1,053	-1,136	0,256
	0,934	0,827	1,055	-1,102	0,270



One-way sensitivity analysis

C. Major bleeding

Risk of major bleedings: Dabigatran (any dose) vs any comparators

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	0,945	0,753	1,186	-0,487	0,626
PETRO	0,882	0,790	0,985	-2,220	0,026
RE-COVER	0,886	0,792	0,992	-2,108	0,035
RE-MEDY	0,898	0,803	1,005	-1,877	0,061
RE-NOVATE	0,878	0,784	0,982	-2,269	0,023
RE-MODEL	0,881	0,788	0,985	-2,230	0,026
RE-NOVATE II	0,875	0,783	0,978	-2,347	0,019
RE-MOBILIZE	0,896	0,801	1,001	-1,941	0,052
RE-DEEM	0,879	0,787	0,982	-2,288	0,022
RE-SONATE	0,881	0,789	0,984	-2,245	0,025
BISTRO II	0,870	0,778	0,974	-2,429	0,015
Fuji	0,882	0,789	0,985	-2,231	0,026
RE-COVER II	0,891	0,796	0,996	-2,024	0,043
RE-ALIGN	0,881	0,788	0,984	-2,251	0,024
	0,884	0,792	0,987	-2,188	0,029



One-way sensitivity analysis

D. All-cause mortality

Risk of death: Dabigatran (any dose) vs any comparators

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	0,875	0,648	1,182	-0,868	0,385
RE-COVER	0,889	0,796	0,993	-2,078	0,038
RE-MEDY	0,892	0,799	0,997	-2,019	0,044
RE-NOVATE	0,887	0,795	0,989	-2,163	0,031
RE-MODEL	0,892	0,800	0,995	-2,050	0,040
RE-NOVATE II	0,894	0,801	0,997	-2,021	0,043
RE-MOBILIZE	0,890	0,798	0,993	-2,087	0,037
RE-DEEM	0,904	0,810	1,009	-1,799	0,072
RE-SONATE	0,895	0,803	0,998	-1,993	0,046
RE-COVER II	0,888	0,795	0,992	-2,093	0,036
RE-ALIGN	0,895	0,803	0,998	-1,994	0,046
	0,892	0,800	0,995	-2,048	0,041



One-way sensitivity analysis

Figure 2: One-way sensitivity analysis for dabigatran etexilate versus warfarin (Fixed-effect model)

A. Myocardial infarction

Risk of myocardial infarction : Dabigatran (any dose) vs Warfarin

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	3,227	1,507	6,908	3,017	0,003
PETRO	1,405	1,103	1,791	2,752	0,006
RE-COVER	1,399	1,095	1,787	2,689	0,007
RE-MEDY	1,332	1,040	1,705	2,274	0,023
RE-ALIGN	1,393	1,092	1,776	2,671	0,008
RE-COVER II	1,399	1,095	1,786	2,687	0,007
	1,409	1,107	1,795	2,781	0,005



Sensitivity analysis

B. Other cardiovascular events

Risk of others cardiovascular diseases: Dabigatran (any dose) vs Warfarin

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	1,326	0,301	5,841	0,373	0,709
RE-COVER	0,935	0,826	1,059	-1,052	0,293
RE-MEDY	0,933	0,824	1,057	-1,085	0,278
	0,935	0,826	1,059	-1,051	0,293



One-way sensitivity analysis

C. Major bleeding

Risk of major bleedings: Dabigatran (any dose) vs Warfarin

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	0,730	0,516	1,034	-1,771	0,077
PETRO	0,847	0,752	0,954	-2,737	0,006
RE-COVER	0,850	0,753	0,960	-2,629	0,009
RE-MEDY	0,864	0,766	0,975	-2,378	0,017
RE-COVER II	0,855	0,758	0,965	-2,537	0,011
RE-ALIGN	0,845	0,750	0,952	-2,772	0,006
	0,849	0,754	0,956	-2,702	0,007



One-way sensitivity analysis

D. All-cause mortality

Risk of death: Dabigatran (any dose) vs Warfarin

Study name	Statistics with study removed				
	Point	Lower limit	Upper limit	Z-Value	p-Value
RE-LY	0,940	0,665	1,328	-0,350	0,726
RE-COVER	0,896	0,801	1,003	-1,902	0,057
RE-MEDY	0,900	0,804	1,007	-1,842	0,065
RE-COVER II	0,895	0,800	1,002	-1,917	0,055
RE-ALIGN	0,902	0,808	1,008	-1,819	0,069
	0,900	0,805	1,005	-1,874	0,061



One-way sensitivity analysis

Figure 3: Evaluation of publication bias

A. Myocardial infarction



Bias Publication Tests	Results	p-value	Interpretation
Egger's Test of the Intercept	0.418	0.152	No evidence of bias
Begg and Mazumdar Rank Correlation Test	0.106	0.316	No evidence of bias

B. Other cardiovascular events



Bias Publication Tests	Results	p-value	Interpretation
Egger's Test of the Intercept	0.194	0.225	No evidence of bias
Begg and Mazumdar Rank Correlation Test	0.167	0.367	No evidence of bias

C. Major bleeding :



Bias Publication Tests	Results	p-value	Interpretation
Egger's Test of the Intercept	0.562	0.090	No evidence of bias
Begg and Mazumdar Rank Correlation Test	0.264	0.090	No evidence of bias

D. All-cause mortality



Bias Publication Tests	Results	p-value	Interpretation
Egger's Test of the Intercept	-0.144	0.365	No evidence of bias
Begg and Mazumdar Rank Correlation Test	-0.182	0.218	No evidence of bias